Table 2 Apolipoprotein E genotype distribution, baseline characteristics of the study population and use of AHDs during follow-up
Apolipoprotein E genotype | ||||||
|---|---|---|---|---|---|---|
ɛ2/3 | ɛ2/4 | ɛ3/3 | ɛ3/4 | ɛ4/4 | All subjects | |
Number of subjects (%) | 161 (11.4) | 20 (1.4) | 892 (63.4) | 309 (22.0) | 25 (1.8) | 1407 (100.0) |
Females (%) | 58.4 | 50.0 | 61.6 | 60.2 | 48.0 | 60.5 |
Mean (s.d.) | ||||||
Age (years) | 68.4 (6.7) | 71.5 (7.0) | 69.2 (7.1) | 69.1 (7.4) | 67.9 (7.1) | 69.1 (7.1) |
LDL cholesterol (mg dl−1) | 140.3 (42.1) | 123.8 (36.2) | 155.9 (45.1) | 160.3 (45.1) | 178.7 (55.1) | 155.0 (45.4) |
Triglycerides (mg dl−1) | 167.6 (144.2) | 132.8 (51.6) | 147.8 (92.6) | 154.1 (97.3) | 145.2 (74.8) | 151.2 (100.3) |
HDL cholesterol (mg dl−1) | 50.6 (16.0) | 60.3 (23.1) | 49.1 (14.7) | 48.0 (14.9) | 50 (16.2) | 49.2 (15.1) |
Glucose (mg dl−1) | 113.4 (46.9) | 116.6 (54.7) | 106.3 (38.4) | 110.3 (51.2) | 111.0 (27.9) | 108.2 (42.7) |
Uric acid (mg dl−1) | 5.2 (1.7) | 6.0 (3.8) | 5.4 (1.7) | 5.2 (1.5) | 5.2 (1.9) | 5.3 (1.7) |
AHD use (%) | ||||||
No | 21.7 | 25.0 | 19.2 | 18.4 | 16.0 | 19.3 |
Irregular | 18.6 | 20.0 | 19.7 | 23.0 | 20.0 | 20.3 |
Frequent | 31.1 | 40.0 | 26.0 | 31.1 | 36.0 | 28.1 |
Yes | 28.6 | 15.0 | 35.1 | 27.5 | 28.0 | 32.3 |
